- cafead Feb 11, 2021 at 11:12: AM
via AC Immune announced it has “remarkable,” “unprecedented” results on an Alzheimer’s vaccine. You’re just not allowed to see the data.
On Thursday, the J&J-partnered Swiss biotech said that its vaccine had generated “high” levels of antibodies against tau, a tangled protein commonly implicated in Alzheimer’s, in every patient in their Phase I/II trial for the neurodegenerative disease. The stock $ACIU instantly doubled in pre-market trading, rising from $7.30 to $14.70, and briefly making AC Immune once again a $1 billion company.
article source
On Thursday, the J&J-partnered Swiss biotech said that its vaccine had generated “high” levels of antibodies against tau, a tangled protein commonly implicated in Alzheimer’s, in every patient in their Phase I/II trial for the neurodegenerative disease. The stock $ACIU instantly doubled in pre-market trading, rising from $7.30 to $14.70, and briefly making AC Immune once again a $1 billion company.
article source